Base de dados : MEDLINE
Pesquisa : C04.557.450.565.575.650 [Categoria DeCS]
Referências encontradas : 19338 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1934 ir para página                         

  1 / 19338 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29505531
[Au] Autor:Li Y; Ye T; Gu Q; Dong L; Chen G; Lu S
[Ad] Endereço:Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University.
[Ti] Título:Primary, cardiac, fibroblastic osteosarcoma: A case report.
[So] Source:Medicine (Baltimore);97(1):e9543, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Primary cardiac osteosarcoma is a rare tumor. To our knowledge, only 15 cases have been reported in the literature in the past 10 years. We describe a case of primary, cardiac, fibroblastic osteosarcoma in a 42-year-old woman. PATIENT CONCERNS: A 42-year-old woman with a 10-day history of chest pain. Intraoperatively, a mass was found originating from the ostium of the left inferior pulmonary vein in the left atrium, extending to the mitral orifice. Histologically, the tumor contained variable amounts of spindle cells and osseous differentiation in different areas. Primary, cardiac fibroblastic osteosarcoma had the typical appearance of interlacing hyperchromatic spindle-shaped stromal cells associated with osseous matrix. DIAGNOSES: According to the clinicopathological features, diagnosis of primary, cardiac fibroblastic osteosarcoma was made. INTERVENTIONS: Wide surgical excision of the mass was performed. OUTCOMES: Three months after the operation, transthoracic echocardiography demonstrated a 3.2 cm × 2 cm recurrent mass in the wall of the left atrium (LA). She died shortly afterwards as a result of the local disease recurrence. LESSONS: In this report, we describe a rare case of primary, cardiac fibroblastic osteosarcoma, and findings are helpful for the pathologists would like to further identify the clinicopathological features of this rare tumor.
[Mh] Termos MeSH primário: Neoplasias Cardíacas/diagnóstico por imagem
Miocárdio/patologia
Osteossarcoma/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adulto
Evolução Fatal
Feminino
Neoplasias Cardíacas/patologia
Seres Humanos
Osteossarcoma/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180306
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009543


  2 / 19338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28954302
[Au] Autor:Fidler MM; Reulen RC; Winter DL; Allodji RS; Bagnasco F; Bárdi E; Bautz A; Bright CJ; Byrne J; Feijen EAM; Garwicz S; Grabow D; Gudmundsdottir T; Guha J; Haddy N; Jankovic M; Kaatsch P; Kaiser M; Kuonen R; Linge H; Maule M; Merletti F; Øfstaas H; Ronckers CM; Skinner R; Teepen J; Terenziani M; Vu-Bezin G; Wesenberg F; Wiebe T; Jakab Z; Haupt R; Lähteenmäki P; Zaletel LZ; Kuehni CE; Winther JF; de Vathaire F; Kremer LC; Hjorth L; Hawkins MM
[Ad] Endereço:Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK; Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France; Cancer and Radiation Team, U1018 INSERM, Villejuif, France; Epidemiology and Biosta
[Ti] Título:Risk of Subsequent Bone Cancers Among 69 460 Five-Year Survivors of Childhood and Adolescent Cancer in Europe.
[So] Source:J Natl Cancer Inst;110(2), 2018 Feb 01.
[Is] ISSN:1460-2105
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Introduction: We investigate the risks of subsequent primary bone cancers after childhood and adolescent cancer in 12 European countries. For the first time, we satisfactorily address the risks beyond 40 years from diagnosis and beyond 40 years of age among all survivors. Methods: This largest-ever assembled cohort comprises 69 460 five-year survivors of cancer diagnosed before age 20 years. Standardized incidence ratios, absolute excess risks, and multivariable-adjusted relative risks and relative excess risks were calculated. All statistical tests were two-sided. Results: Overall, survivors were 21.65 times (95% confidence interval = 18.97 to 24.60 times) more likely to be diagnosed with a subsequent primary bone cancer than expected from the general population. The greatest excess numbers of bone cancers were observed after retinoblastoma, bone sarcoma, and soft tissue sarcoma. The excess number of bone cancers declined linearly with both years since diagnosis and attained age (all P < .05). Beyond 40 years from diagnosis and age 40 years, there were at most 0.45 excess bone cancers among all survivors per 10 000 person-years at risk; beyond 30 years from diagnosis and age 30 years, there were at most 5.02 excess bone cancers after each of retinoblastoma, bone sarcoma, and soft tissue sarcoma, per 10 000 person-years at risk. Conclusions: For all survivors combined and the cancer groups with the greatest excess number of bone cancers, the excess numbers observed declined with both age and years from diagnosis. These results provide novel, reliable, and unbiased information about risks and risk factors among long-term survivors of childhood and adolescent cancer.
[Mh] Termos MeSH primário: Neoplasias Ósseas/epidemiologia
Segunda Neoplasia Primária/epidemiologia
Sobreviventes/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Estudos de Coortes
Europa (Continente)/epidemiologia
Feminino
Seguimentos
Seres Humanos
Masculino
Osteossarcoma/epidemiologia
Retinoblastoma/epidemiologia
Sarcoma/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1093/jnci/djx165


  3 / 19338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29303365
[Au] Autor:Xiao Y; Zhao Q; Du B; Chen HY; Zhou DZ
[Ad] Endereço:a Department of Orthopaedic , The People's Hospital of Kaizhou District , Chongqing , PR China.
[Ti] Título:MicroRNA-187 Inhibits Growth and Metastasis of Osteosarcoma by Downregulating S100A4.
[So] Source:Cancer Invest;36(1):1-9, 2018 Jan 02.
[Is] ISSN:1532-4192
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Abnormal expression and dysfunction of microRNAs are correlated with osteosarcoma (OS). This study demonstrated that the miR-187 level in OS tissues and cell lines was decreased. The proliferation and metastatic abilities of U-2OS cells were inhibited by miR-187 overexpression and promoted by miR-187 knockdown. Moreover, miR-187 also inhibited growth and metastasis of OS cells in vivo. Furthermore, we revealed that miR-187 could interact with S100A4 3'-UTR and inhibit S100A4 expression in OS cells. In summary, miR-187 inhibits growth and metastasis of OS cells by downregulating S100A4, which might be a potential biomarker and therapeutic target of OS.
[Mh] Termos MeSH primário: Neoplasias Ósseas/genética
Proliferação Celular/genética
Regulação para Baixo/genética
MicroRNAs/genética
Metástase Neoplásica/genética
Osteossarcoma/genética
Proteína A4 de Ligação a Cálcio da Família S100/genética
[Mh] Termos MeSH secundário: Regiões 3' não Traduzidas/genética
Neoplasias Ósseas/patologia
Linhagem Celular Tumoral
Movimento Celular/genética
Regulação Neoplásica da Expressão Gênica/genética
Seres Humanos
Metástase Neoplásica/patologia
Osteossarcoma/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (3' Untranslated Regions); 0 (MIRN187 microRNA, human); 0 (MicroRNAs); 0 (S100 Calcium-Binding Protein A4); 142662-27-9 (S100A4 protein, human)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180106
[St] Status:MEDLINE
[do] DOI:10.1080/07357907.2017.1415348


  4 / 19338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460433
[Au] Autor:Cheng DD; Zhang HZ; Yuan JQ; Li SJ; Yang QC; Fan CY
[Ad] Endereço:Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China.
[Ti] Título:Minichromosome maintenance protein 2 and 3 promote osteosarcoma progression via DHX9 and predict poor patient prognosis.
[So] Source:Oncotarget;8(16):26380-26393, 2017 Apr 18.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A label free quantitative proteomic approach (SWATH™ experiment) was performed to identify tumor-associated nuclear proteins that are differentially expressed between osteosarcoma cells and osteoblast cells. By functional screening, minichromosome maintenance protein 2 (MCM2) and minichromosome maintenance protein 3 (MCM3) were found to be related to osteosarcoma cell growth. Here, we show that knockdown of MCM2 or MCM3 inhibits osteosarcoma growth in vitro and in vivo. In co-immunoprecipitation and co-localization experiments, MCM2 and MCM3 were found to interact with DExH-box helicase 9 (DHX9) in osteosarcoma cells. A rescue study showed that the decreased growth of osteosarcoma cells by MCM2 or MCM3 knockdown was reversed by DHX9 overexpression, indicating that MCM2 and MCM3 activity was DHX9-dependent. In addition, the depletion of DHX9 hindered osteosarcoma cell proliferation. Notably, MCM2 and MCM3 expression levels were positively correlated with the DHX9 expression level in tumor samples and were associated with a poor prognosis in patients with osteosarcoma. Taken together, these results suggest that the MCM2/MCM3-DHX9 axis has an important role in osteosarcoma progression.
[Mh] Termos MeSH primário: Neoplasias Ósseas/metabolismo
Neoplasias Ósseas/mortalidade
RNA Helicases DEAD-box/metabolismo
Componente 2 do Complexo de Manutenção de Minicromossomo/metabolismo
Componente 3 do Complexo de Manutenção de Minicromossomo/metabolismo
Proteínas de Neoplasias/metabolismo
Osteossarcoma/metabolismo
Osteossarcoma/mortalidade
[Mh] Termos MeSH secundário: Adolescente
Adulto
Animais
Neoplasias Ósseas/genética
Neoplasias Ósseas/patologia
Linhagem Celular Tumoral
Proliferação Celular/genética
Criança
Modelos Animais de Doenças
Progressão da Doença
Feminino
Expressão Gênica
Técnicas de Silenciamento de Genes
Xenoenxertos
Seres Humanos
Masculino
Camundongos
Componente 2 do Complexo de Manutenção de Minicromossomo/genética
Componente 3 do Complexo de Manutenção de Minicromossomo/genética
Metástase Neoplásica
Estadiamento de Neoplasias
Proteínas Nucleares/metabolismo
Osteossarcoma/genética
Osteossarcoma/patologia
Prognóstico
Modelos de Riscos Proporcionais
Ligação Proteica
Proteoma
Proteômica/métodos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (MCM3 protein, human); 0 (Neoplasm Proteins); 0 (Nuclear Proteins); 0 (Proteome); EC 3.6.1.- (DHX9 protein, human); EC 3.6.4.12 (MCM2 protein, human); EC 3.6.4.12 (Minichromosome Maintenance Complex Component 2); EC 3.6.4.12 (Minichromosome Maintenance Complex Component 3); EC 3.6.4.13 (DEAD-box RNA Helicases)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.15474


  5 / 19338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463156
[Au] Autor:Demizu Y; Jin D; Sulaiman NS; Nagano F; Terashima K; Tokumaru S; Akagi T; Fujii O; Daimon T; Sasaki R; Fuwa N; Okimoto T
[Ad] Endereço:Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan. Electronic address: y_demizu@nifty.com.
[Ti] Título:Particle Therapy Using Protons or Carbon Ions for Unresectable or Incompletely Resected Bone and Soft Tissue Sarcomas of the Pelvis.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):367-374, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To retrospectively analyze the treatment outcomes of particle therapy using protons or carbon ions for unresectable or incompletely resected bone and soft tissue sarcomas (BSTSs) of the pelvis. METHODS AND MATERIALS: From May 2005 to December 2014, 91 patients with nonmetastatic histologically proven unresectable or incompletely resected pelvic BSTSs underwent particle therapy with curative intent. The particle therapy used protons (52 patients) or carbon ions (39 patients). All patients received a dose of 70.4 Gy (relative biologic effectiveness) in 32 fractions (55 patients) or 16 fractions (36 patients). RESULTS: The median patient age was 67 years (range 18-87). The median planning target volume (PTV) was 455 cm (range 108-1984). The histologic type was chordoma in 53 patients, chondrosarcoma in 14, osteosarcoma in 10, malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma in 5, and other in 9 patients. Of the 91 patients, 82 had a primary tumor and 9 a recurrent tumor. The median follow-up period was 32 months (range 3-112). The 3-year rate of overall survival (OS), progression-free survival (PFS), and local control was 83%, 72%, and 92%, respectively. A Cox proportional hazards model revealed that chordoma histologic features and a PTV of ≤500 cm were significantly associated with better OS, and a primary tumor and PTV of ≤500 cm were significantly associated with better PFS. Ion type and number of fractions were not significantly associated with OS, PFS, or local control. Late grade ≥3 toxicities were observed in 23 patients. Compared with the 32-fraction protocol, the 16-fraction protocol was associated with significantly more frequent late grade ≥3 toxicities (18 of 36 vs 5 of 55; P<.001). CONCLUSIONS: Particle therapy using protons or carbon ions was effective for unresectable or incompletely resected pelvic BSTS, and the 32-fraction protocol was effective and relatively less toxic. Nevertheless, a longer follow-up period is needed to confirm these results.
[Mh] Termos MeSH primário: Neoplasias Ósseas/radioterapia
Radioterapia com Íons Pesados/métodos
Ossos Pélvicos
Terapia com Prótons/métodos
Sarcoma/radioterapia
[Mh] Termos MeSH secundário: Idoso
Neoplasias Ósseas/diagnóstico por imagem
Neoplasias Ósseas/mortalidade
Neoplasias Ósseas/cirurgia
Condrossarcoma/mortalidade
Condrossarcoma/radioterapia
Condrossarcoma/cirurgia
Cordoma/diagnóstico por imagem
Cordoma/mortalidade
Cordoma/radioterapia
Cordoma/cirurgia
Feminino
Radioterapia com Íons Pesados/estatística & dados numéricos
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Osteossarcoma/mortalidade
Osteossarcoma/radioterapia
Osteossarcoma/cirurgia
Ossos Pélvicos/diagnóstico por imagem
Modelos de Riscos Proporcionais
Terapia com Prótons/estatística & dados numéricos
Planejamento da Radioterapia Assistida por Computador/métodos
Eficiência Biológica Relativa
Estudos Retrospectivos
Sarcoma/diagnóstico por imagem
Sarcoma/mortalidade
Sarcoma/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  6 / 19338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29291409
[Au] Autor:Huang J; Deng G; Liu T; Chen W; Zhou Y
[Ad] Endereço:Department of Orthopaedic Surgery, The First Affiliated Hospital of Nanchang University, No. 17 Yong Waizheng Street, Nanchang 330006, China. Electronic address: hj121479@sina.com.
[Ti] Título:Long noncoding RNA PCAT-1 acts as an oncogene in osteosarcoma by reducing p21 levels.
[So] Source:Biochem Biophys Res Commun;495(4):2622-2629, 2018 01 22.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Long non-coding RNA (lncRNA) is emerging as a critical regulator in multiple cancers. Recently, lncRNA PCAT-1 was found to be up-regulated in prostate cancer and hepatocellular carcinoma, exerting oncogenic effects. However, the biological function and regulatory mechanism of PCAT-1 remain unclear in osteosarcoma (OS). In this study, we reported that PCAT-1 expression was also upregulated in OS tissues, and its overexpression was remarkably associated with tumor size, Enneking stage, tumor node metastasis (TNM) stage and metastasis in patients with OS. Knockdown of PCAT-1 suppressed OS cells proliferation, migration and invasion in vitro, and inhibited the tumorigenicity of OS cells in vivo. Mechanistic investigations revealed that PCAT-1 could interact with EZH2, thereby repressing p21 expression. Additionally, rescue experiments indicated that PCAT-1 functioned as an oncogene partly via suppressing p21 in OS cells. Collectively, our findings demonstrate that PCAT-1 is a new candidate for use in OS diagnosis, prognosis and therapy.
[Mh] Termos MeSH primário: Transformação Celular Neoplásica/genética
Inibidor de Quinase Dependente de Ciclina p21/metabolismo
Oncogenes/genética
Osteossarcoma/genética
Osteossarcoma/patologia
RNA Longo não Codificante/genética
[Mh] Termos MeSH secundário: Animais
Movimento Celular/genética
Proliferação Celular
Transformação Celular Neoplásica/patologia
Regulação para Baixo/genética
Regulação Neoplásica da Expressão Gênica/genética
Técnicas de Silenciamento de Genes
Terapia Genética/métodos
Seres Humanos
Masculino
Camundongos
Camundongos Endogâmicos BALB C
Invasividade Neoplásica/genética
Osteossarcoma/terapia
Células Tumorais Cultivadas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cdkn1a protein, mouse); 0 (Cyclin-Dependent Kinase Inhibitor p21); 0 (PCAT-1 lncRNA, human); 0 (RNA, Long Noncoding)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180102
[St] Status:MEDLINE


  7 / 19338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390436
[Au] Autor:Jiang S; Wang G; Dong Y
[Ad] Endereço:Department of Medical Oncology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
[Ti] Título:Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report.
[So] Source:Medicine (Baltimore);96(51):e9077, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Angiogenesis is a key factor for tumor growth and metastasis both in cancer and sarcoma. Endostar, a novel safe and well-tolerated recombinant human endostatin, can suppress the expression of VEGF and the activation of ERK, MAPK, and AKT, and then inhibit tumor progression. PATIENT CONCERNS: A pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion. DIAGNOSES: Osteosarcoma with pulmonary metastasis and malignant pleural effusion. INTERVENTIONS: Considering the physical condition of patient, the patient underwent surgical resection of the right lung lesion after receiving endostar combined with chemotherapy and maintained endostar alone for 47 cycles. OUTCOMES: The patient obtained pathologic complete remission and had been in progression-free survival up to now. LESSONS: Our experience could provide a treatment strategy for pediatric osteosarcoma patients with pulmonary metastasis and malignant pleural effusion.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias Ósseas/tratamento farmacológico
Endostatinas/administração & dosagem
Neoplasias Pulmonares/tratamento farmacológico
Neoplasias Pulmonares/secundário
Osteossarcoma/tratamento farmacológico
[Mh] Termos MeSH secundário: Neoplasias Ósseas/patologia
Criança
Etoposídeo/administração & dosagem
Seres Humanos
Ifosfamida/administração & dosagem
Neoplasias Pulmonares/cirurgia
Osteossarcoma/patologia
Osteossarcoma/secundário
Osteossarcoma/cirurgia
Derrame Pleural Maligno/tratamento farmacológico
Derrame Pleural Maligno/etiologia
Derrame Pleural Maligno/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Endostatins); 0 (endostar protein); 6PLQ3CP4P3 (Etoposide); UM20QQM95Y (Ifosfamide)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009077


  8 / 19338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29225166
[Au] Autor:Zheng B; Ren T; Huang Y; Guo W
[Ad] Endereço:Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, People's Republic of China; Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China.
[Ti] Título:Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
[So] Source:Biochem Biophys Res Commun;495(2):1695-1701, 2018 01 08.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The cure rate of osteosarcoma has not improved in the past 30 years. The new treatments and drugs is urgently needed, especially for metastatic osteosarcoma. Anti-angiogenesis therapy and immunotherapy has got promising anti-tumor effects in various tumors. It is hypothesised that combining checkpoint inhibitor immunotherapies with antiangiogenic treatment may have a synergistic effect and enhance the efficacy of both treatments. However, its underlying mechanism remain largely uninvestigated. To investigate the clinical significance of vascular endothelial growth factor receptor-2 (VEGFR2) and programmed death ligand-1 (PD-L1) in osteosarcoma, we analyzes their expression levels in 93 osteosarcoma specimens by immunohistochemistry. Meanwhile, we analyzes their correlation with the metastatic behavior and overall survival (OS). We also investigate the effects of Apatinib on migration and invasion of osteosarcoma cells and its underlying mechanism in vitro and in vivo. In our study, the positive rates of the VEGFR2 and PD-L1 expression are 64.5% (60/93) and 35.5% (33/93), respectively. A significant correlation is detected between VEGFR2 and PD-L1 expression (P = 0.009). Receiver-operating characteristic (ROC) curves analysis indicates the predictive value of the two markers in tumor metastasis, and both PD-L1 and VEGFR2 are negatively correlated with OS. Transwell assays reveals that VEGFR2 inhibition attenuates migration and invasion of osteosarcoma cells. Mechanistically, we demonstrate that Apatinib attenuates migration and invasion by suppressing epithelial-mesenchymal transition (EMT) and inactivating STAT3. Additionally, Apatinib reduces PD-L1 expression in osteosarcoma cells. Apatinib markedly weakens pulmonary metastatic potential of osteosarcoma in vivo. In conclusion, our study reveals a pro-metastatic functional mechanism for VEGFR2 in osteosarcoma. Furthermore, we demonstrate that Apatinib exerts anti-tumor effect not only through antiangiogenic effect, but also via suppressing immune escape, which may represent a potential therapeutic target for metastatic osteosarcoma.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Antígeno B7-H1/metabolismo
Neoplasias Ósseas/tratamento farmacológico
Osteossarcoma/tratamento farmacológico
Piridinas/farmacologia
Fator de Transcrição STAT3/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Biomarcadores Tumorais/antagonistas & inibidores
Biomarcadores Tumorais/metabolismo
Neoplasias Ósseas/metabolismo
Neoplasias Ósseas/patologia
Linhagem Celular Tumoral
Movimento Celular/efeitos dos fármacos
Transição Epitelial-Mesenquimal/efeitos dos fármacos
Feminino
Seres Humanos
Imuno-Histoquímica
Neoplasias Pulmonares/prevenção & controle
Neoplasias Pulmonares/secundário
Camundongos
Camundongos Endogâmicos BALB C
Camundongos Nus
Invasividade Neoplásica/prevenção & controle
Osteossarcoma/metabolismo
Osteossarcoma/patologia
Fator de Transcrição STAT3/metabolismo
Receptor 2 de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores
Receptor 2 de Fatores de Crescimento do Endotélio Vascular/metabolismo
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (B7-H1 Antigen); 0 (Biomarkers, Tumor); 0 (CD274 protein, human); 0 (Pyridines); 0 (STAT3 Transcription Factor); 0 (STAT3 protein, human); 5S371K6132 (apatinib); EC 2.7.10.1 (KDR protein, human); EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE


  9 / 19338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455292
[Au] Autor:Harrold E; McMahon E; McGing P; Higgins M
[Ad] Endereço:Mater Misericordiae University Hospital, Dublin, Ireland.
[Ti] Título:ßhCG-secreting osteosarcoma.
[So] Source:BMJ Case Rep;2017, 2017 Apr 28.
[Is] ISSN:1757-790X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A 35-year-old woman presented to our institution with tender, right knee swelling. Radiological and pathological work-up revealed metastatic osteosarcoma. Prior to the initiation of chemotherapy, she underwent a routine urine pregnancy test and was surprised with a positive result. Serum beta human chorionic gonadotropin (ßhCG) levels were also consistently positive and rising. No gestational sac was seen at transvaginal ultrasound. The paraneoplastic ectopic secretion of ßhCG has been well described in gestational trophoblastic and gonadal tumours but has very rarely been associated with other tumour types. This patient's ßhCG level was reflective of osteosarcoma activity and normalised with response to chemotherapy. The prognostic implications of ßhCG expression in more diverse tumours is unclear; however, where raised, it can be used to monitor disease activity.
[Mh] Termos MeSH primário: Gonadotropina Coriônica Humana Subunidade beta/sangue
Joelho/diagnóstico por imagem
Osteossarcoma/sangue
Osteossarcoma/secundário
[Mh] Termos MeSH secundário: Adulto
Assistência ao Convalescente
Gonadotropina Coriônica Humana Subunidade beta/secreção
Feminino
Seres Humanos
Joelho/patologia
Osteossarcoma/patologia
Osteossarcoma/terapia
Dor/diagnóstico
Dor/etiologia
Testes de Gravidez
Prognóstico
Tíbia/patologia
Tíbia/cirurgia
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chorionic Gonadotropin, beta Subunit, Human)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  10 / 19338 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29252655
[Au] Autor:Park A; Cipriano CA; Hill K; Kyriakos M; McDonald DJ
[Ad] Endereço:Departments of Orthopaedic Surgery (A.P., C.A.C., and D.J.M.) and Pathology (K.H. and M.K.), Washington University School of Medicine, St. Louis, Missouri.
[Ti] Título:Malignant Transformation of a Giant Cell Tumor of Bone Treated with Denosumab: A Case Report.
[So] Source:JBJS Case Connect;6(3):e78, 2016 Jul-Sep.
[Is] ISSN:2160-3251
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CASE: Giant cell tumor (GCT) of bone was first described almost 200 years ago, but the optimal treatment continues to evolve. We present a patient with a pelvic GCT who was treated with embolization, 20 months of denosumab therapy, and resection. Histologically, the tumor consisted of degenerated GCT, bone, and fibrous tissue. After 7 months, the patient was found to have osteosarcoma at the site of the initial lesion as well as pulmonary metastases. CONCLUSION: The apparent malignant transformation of a GCT of bone treated initially with denosumab indicates that close follow-up is warranted.
[Mh] Termos MeSH primário: Conservadores da Densidade Óssea/efeitos adversos
Neoplasias Ósseas/patologia
Denosumab/efeitos adversos
Tumor de Células Gigantes do Osso/patologia
Segunda Neoplasia Primária/patologia
Osteossarcoma/patologia
Ossos Pélvicos/patologia
[Mh] Termos MeSH secundário: Adulto
Neoplasias Ósseas/diagnóstico por imagem
Neoplasias Ósseas/tratamento farmacológico
Neoplasias Ósseas/cirurgia
Transformação Celular Neoplásica
Evolução Fatal
Feminino
Tumor de Células Gigantes do Osso/diagnóstico por imagem
Tumor de Células Gigantes do Osso/tratamento farmacológico
Tumor de Células Gigantes do Osso/cirurgia
Seres Humanos
Segunda Neoplasia Primária/etiologia
Osteossarcoma/etiologia
Ossos Pélvicos/diagnóstico por imagem
Ossos Pélvicos/efeitos dos fármacos
Ossos Pélvicos/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 4EQZ6YO2HI (Denosumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.2106/JBJS.CC.16.00024



página 1 de 1934 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde